eye-soe-NYE-a-zid

• First-line therapy of active tuberculosis, in combination with other agents.
• Prevention of tuberculosis in patients exposed to active disease (alone).

• Inhibits mycobacterial cell wall synthesis and interferes with metabolism.

• Bacteriostatic or bactericidal action against susceptible mycobacteria.

Absorption: Well absorbed following PO/IM administration.

Distribution: Widely distributed; readily crosses the blood-brain barrier. Crosses the placenta; enters breast milk in concentrations equal to plasma.

Protein Binding: 10–15%.

Metabolism/Excretion: 50% metabolized by the liver by N-acetyltransferase (rate of acetylation is genetically determined [slow acetylators have ↑ isoniazid levels and ↑ risk of toxicity; fast acetylators have ↓ isoniazid levels and ↑ risk for treatment failure]); 50% excreted unchanged by the kidneys.

Half-life: 1–4 hr in patients with normal renal and hepatic function; 0.5–1.6 hr in fast acetylators; 2–5 hr in slow acetylators.

Contraindicated in:

• Hypersensitivity
• Acute liver disease
• History of hepatitis from previous use.

Use Cautiously in:

• History of liver damage or chronic alcohol ingestion
• Black and Hispanic women, women in the postpartum period, or patients >50 yr (↑ risk of drug-induced hepatitis)
• Severe renal impairment (dose ↓ may be necessary)
• Malnourished patients, patients with diabetes, or chronic alcoholics (↑ risk of neuropathy)
• OB: Lactation: Although safety is not established, isoniazid has been used with ethambutol to treat tuberculosis in pregnant women without harm to the fetus.

EENT: visual disturbances.

GI: DRUG-INDUCED HEPATITIS, nausea, vomiting.

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), TOXIC EPIDERMAL NECROLYSIS, rash.

Endo: gynecomastia.

GI: PANCREATITIS.

Hemat: blood dyscrasias.

Neuro: peripheral neuropathy , psychosis, seizures.

Misc: fever.

Drug-Drug:

• Additive CNS toxicity with other antituberculars.
• BCG vaccine may not be effective during isoniazid therapy.
• Isoniazid ↓ metabolism of and may ↑ levels of phenytoin.
• Aluminum-containing antacids may ↓ absorption.
• Psychotic reactions and coordination difficulties may result with disulfiram.
• Concurrent administration of pyridoxine may prevent neuropathy.
• ↑risk of hepatotoxicity with other hepatotoxic agents including alcohol, acetaminophen, and rifampin.
• Isoniazid may ↓ blood levels and effectiveness of ketoconazole.
• May ↑ carbamazepine levels and risk of hepatotoxicity.
• May ↓ effectiveness of clopidogrel (avoid concurrent use).

Drug-Food:

• Severe reactions may occur with ingestion of foods containing high concentrations of tyramine (see Appendix M).

• PO, IM (Adults): 300 mg/day (5 mg/kg) or 15 mg/kg (up to 900 mg) 2–3 times weekly.
• PO, IM (Children <40 kg): Latent TB infection — 10–20 mg/kg/day (up to 300 mg/day) or 20–40 mg/kg (up to 900 mg) 2 times weekly; Active TB infection — 10–15 mg/kg/day (up to 300 mg/day) or 20–40 mg/kg (up to 900 mg) 2 times weekly.

• PO: Administer on an empty stomach.
• IM: Medication may cause discomfort at injection site. Massage site after administration and rotate injection sites.
  • Solution may form crystals at low temperatures; crystals will redissolve upon warming to room temperature.

Isotamine

Therapeutic Classification: antituberculars

(Generic available)

• Tablets: 50 mg; 100 mg; 300 mg;
• Oral solution (orange, raspberry flavor): 50 mg/5 mL;
• Solution for injection: 100 mg/mL;

(blood levels)

• Mycobacterial studies and susceptibility tests should be performed prior to and periodically during therapy to detect possible resistance. About 50 to 65% of Caucasians, Black, South Indians, and Mexicans are slow acetylators at risk for toxicity, while 80 to 90% of Eskimos, Japanese, and Chinese are rapid acetylators at risk for decreased levels and treatment failure.
• Monitor for signs and symptoms of DRESS (fever, rash, lymphadenopathy, and/or facial swelling, associated with involvement of other organ systems (hepatitis, nephritis, hematologic abnormalities, myocarditis, myositis) during therapy. May resemble an acute viral infection. Eosinophilia is often present. Discontinue therapy if signs occur.
• Assess for rash periodically during therapy. May cause Stevens-Johnson syndrome. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, and/or eosinophilia.

• Hepatic function should be evaluated prior to and monthly throughout therapy. Increased AST, ALT, and serum bilirubin may indicate drug-induced hepatitis. Black and Hispanic women, postpartal women, and patients >50 yr are at highest risk. Risk is lower in children; therefore, liver function tests are usually ordered less frequently for children. If AST, ALT, or serum bilirubin are >3–5 × ULN, temporarily discontinue isoniazid and consider restarting therapy.

• If isoniazid overdose occurs, treatment with pyridoxine (vitamin B) is instituted.

• Advise patient to take medication as directed. Take missed doses as soon as possible unless almost time for next dose; do not double up on missed doses. Emphasize the importance of continuing therapy even after symptoms have subsided. Therapy may be continued for 6 mo–2 yr.
• Advise patient to notify health care professional promptly if signs and symptoms of hepatitis (yellow eyes and skin, nausea, vomiting, anorexia, dark urine, unusual tiredness, or weakness) or peripheral neuritis (numbness, tingling, paresthesia) occur. Pyridoxine may be used concurrently to prevent neuropathy. Any changes in visual acuity, eye pain, or blurred vision should also be reported immediately.
• Caution patient to avoid the use of alcohol during this therapy, as this may increase the risk of hepatotoxicity. Avoid ingestion of Swiss or Cheshire cheeses, fish (tuna, skipjack, and sardinella), and tyramine-containing foods (see Appendix M); may result in redness or itching of the skin; hot feeling; rapid or pounding heartbeat; sweating; chills; cold, clammy feeling; headache; or light-headedness.
• Rep: May be used as treatment for active tuberculosis during pregnancy. Begin preventative therapy after delivery. May increase the risk of isoniazid-associated peripheral neurotoxicity in the mother; pyridoxine supplementation is recommended in pregnant patients during therapy. May be used during breastfeeding as the small concentrations in breast milk do not produce toxicity in the nursing newborn; breast feeding should not be discouraged. Low levels of isoniazid in breast milk can not be relied upon for prophylaxis or therapy in nursing infants. Monitor breastfed infants for jaundice; discontinue breastfeeding or consider changing to a different maternal medication if jaundice develops. Pyridoxine supplementation is recommended for the mother and infant.
• Emphasize the importance of regular follow-up physical and ophthalmologic exams to monitor progress and to check for side effects.

• Resolution of signs and symptoms of tuberculosis.
  • Negative sputum cultures.
• Prevention of activation of tuberculosis in persons known to have been exposed.

NDC Code^*

• 0185- Eon Labs, Inc.
  • 0185-4350- Isoniazid
    • 0185-4350-01- 100 TABLET in 1 BOTTLE (0185-4350-01)

• 0185- Eon Labs, Inc.
  • 0185-4350- Isoniazid
    • 0185-4350-10- 1000 TABLET in 1 BOTTLE (0185-4350-10)

• 0185- Eon Labs, Inc.
  • 0185-4350- Isoniazid
    • 0185-4350-30- 30 TABLET in 1 BOTTLE (0185-4350-30)

• 0185- Eon Labs, Inc.
  • 0185-4351- Isoniazid
    • 0185-4351-01- 100 TABLET in 1 BOTTLE (0185-4351-01)

• 0527- Lannett Company, Inc.
  • 0527-1109- Isoniazid
    • 0527-1109-01- 100 TABLET in 1 BOTTLE (0527-1109-01)

• 0527- Lannett Company, Inc.
  • 0527-1109- Isoniazid
    • 0527-1109-10- 1000 TABLET in 1 BOTTLE (0527-1109-10)

• 0527- Lannett Company, Inc.
  • 0527-1109- Isoniazid
    • 0527-1109-30- 30 TABLET in 1 BOTTLE (0527-1109-30)

• 0555- Teva Pharmaceuticals USA, Inc.
  • 0555-0066- Isoniazid
    • 0555-0066-02- 100 TABLET in 1 BOTTLE (0555-0066-02)

• 0555- Teva Pharmaceuticals USA, Inc.
  • 0555-0071- Isoniazid
    • 0555-0071-01- 30 TABLET in 1 BOTTLE, UNIT-DOSE (0555-0071-01)

• 0555- Teva Pharmaceuticals USA, Inc.
  • 0555-0071- Isoniazid
    • 0555-0071-02- 100 TABLET in 1 BOTTLE (0555-0071-02)

• 0555- Teva Pharmaceuticals USA, Inc.
  • 0555-0071- Isoniazid
    • 0555-0071-05- 1000 TABLET in 1 BOTTLE (0555-0071-05)

• 0781- Sandoz Inc
  • 0781-3056- Isoniazid
    • 0781-3056-70- 1 VIAL, MULTI-DOSE in 1 CARTON (0781-3056-70) > 10 mL in 1 VIAL, MULTI-DOSE

• 43063- PD-Rx Pharmaceuticals, Inc.
  • 43063-463- Isoniazid
    • 43063-463-30- 30 TABLET in 1 BOTTLE, PLASTIC (43063-463-30)

• 46287- CMP Pharma, Inc.
  • 46287-009- Isoniazid
    • 46287-009-01- 473 mL in 1 BOTTLE (46287-009-01)

• 46672- Mikart, LLC
  • 46672-597- isoniazid
    • 46672-597-16- 473 mL in 1 BOTTLE (46672-597-16)

• 46672- Mikart, Inc.
  • 46672-865- isoniazid
    • 46672-865-10- 100 TABLET in 1 BOTTLE, PLASTIC (46672-865-10)

• 46672- Mikart, Inc.
  • 46672-866- isoniazid
    • 46672-866-03- 30 TABLET in 1 BOTTLE, PLASTIC (46672-866-03)

• 46672- Mikart, Inc.
  • 46672-866- isoniazid
    • 46672-866-10- 100 TABLET in 1 BOTTLE, PLASTIC (46672-866-10)

• 46672- Mikart, Inc.
  • 46672-866- isoniazid
    • 46672-866-11- 1000 TABLET in 1 BOTTLE, PLASTIC (46672-866-11)

• 50090- A-S Medication Solutions
  • 50090-0370- Isoniazid
    • 50090-0370-3- 30 TABLET in 1 BOTTLE (50090-0370-3)

• 50090- A-S Medication Solutions
  • 50090-0410- Isoniazid
    • 50090-0410-0- 100 TABLET in 1 BOTTLE (50090-0410-0)

• 51079- Mylan Institutional Inc.
  • 51079-083- Isoniazid
    • 51079-083-20- 100 BLISTER PACK in 1 CARTON (51079-083-20) > 1 TABLET in 1 BLISTER PACK (51079-083-01)

• 51655- Northwind Pharmaceuticals, LLC
  • 51655-391- Isoniazid
    • 51655-391-24- 30 TABLET in 1 BOTTLE, DISPENSING (51655-391-24)

• 53002- RPK Pharmaceuticals, Inc.
  • 53002-2920- Isoniazid
    • 53002-2920-0- 100 TABLET in 1 BOTTLE (53002-2920-0)

• 53002- RPK Pharmaceuticals, Inc.
  • 53002-2920- Isoniazid
    • 53002-2920-3- 30 TABLET in 1 BOTTLE (53002-2920-3)

• 53002- RPK Pharmaceuticals, Inc.
  • 53002-2920- Isoniazid
    • 53002-2920-6- 60 TABLET in 1 BOTTLE (53002-2920-6)

• 53808- State of Florida DOH Central Pharmacy
  • 53808-1041- Isoniazid
    • 53808-1041-1- 30 TABLET in 1 BLISTER PACK (53808-1041-1)

• 60687- American Health Packaging
  • 60687-158- Isoniazid
    • 60687-158-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-158-01) > 1 TABLET in 1 BLISTER PACK (60687-158-11)

• 63187- Proficient Rx LP
  • 63187-978- Isoniazid
    • 63187-978-30- 30 TABLET in 1 BOTTLE (63187-978-30)

• 63187- Proficient Rx LP
  • 63187-978- Isoniazid
    • 63187-978-60- 60 TABLET in 1 BOTTLE (63187-978-60)

• 63187- Proficient Rx LP
  • 63187-978- Isoniazid
    • 63187-978-90- 90 TABLET in 1 BOTTLE (63187-978-90)

• 66267- NuCare Pharmaceuticals, Inc.
  • 66267-124- Isoniazid
    • 66267-124-30- 30 TABLET in 1 BOTTLE (66267-124-30)

• 68788- Preferred Pharmaceuticals, Inc.
  • 68788-9405- Isoniazid
    • 68788-9405-1- 100 TABLET in 1 BOTTLE (68788-9405-1)

• 68788- Preferred Pharmaceuticals, Inc.
  • 68788-9405- Isoniazid
    • 68788-9405-3- 30 TABLET in 1 BOTTLE (68788-9405-3)

• 68788- Preferred Pharmaceuticals, Inc.
  • 68788-9405- Isoniazid
    • 68788-9405-6- 60 TABLET in 1 BOTTLE (68788-9405-6)

• 68788- Preferred Pharmaceuticals, Inc.
  • 68788-9405- Isoniazid
    • 68788-9405-9- 90 TABLET in 1 BOTTLE (68788-9405-9)

• 70518- REMEDYREPACK INC.
  • 70518-0096- Isoniazid
    • 70518-0096-0- 30 TABLET in 1 BOTTLE (70518-0096-0)

• 70518- REMEDYREPACK INC.
  • 70518-0595- Isoniazid
    • 70518-0595-0- 30 TABLET in 1 BLISTER PACK (70518-0595-0)

• 70518- REMEDYREPACK INC.
  • 70518-1491- Isoniazid
    • 70518-1491-0- 30 TABLET in 1 BLISTER PACK (70518-1491-0)

• 71610- Aphena Pharma Solutions - Tennessee, LLC
  • 71610-108- Isoniazid
    • 71610-108-30- 30 TABLET in 1 BOTTLE (71610-108-30)